Exactly, We preparing the protocol ( protocols a
Post# of 158771
We preparing the protocol ( protocols are for a trials , this is why they said we will talk with FDA about it ) if any patient remain stable can continue LL treatment beyond 48 weeks...
--" If any patient remain stable " .... well , maybe none will beyond 48 weeks ...
So read below again ..
With that in mind, we have prepared a rollover protocol to ensure that CRC patients who remain stable can continue leronlimab treatment beyond 48 weeks and to allow patients with disease progression the opportunity to receive leronlimab at a dose of 700 mg in combination with an ICI.